• Home
  • PR



게시물 상세
Updated Data_OLX301A
Date : 2019-05-23     View : 2219

OliX Pharmaceuticals (KOSDAQ: 226950) gives the Poster Presentation with Updated Data from ongoing Wet & Dry AMD Preclinical studies of OLX301A in the CNV model of Rhesus Monkeys at #TIDES in San Diego on May 23.


Prev OliX Pharmaceuticals Announces Publication of Peer Reviewed Study in Molecular Pharmaceutics
Next OliX Pharmaceuticals Expands Ocular Disease Pipeline; Adds OLX304A for the Treatment of Retinitis Pi